According to reports from CNBC TV18 and ET Now, Concord Biotech's board of directors is scheduled to meet on Wednesday, September 23, to consider a proposal to declare bonus equity shares to existing shareholders. The company informed exchanges on September 19 that this will mark the first instance that the company will be issuing bonus shares to its shareholders, as per the regulatory filing. The proposal was approved at the company's Board meeting held on Wednesday, September 23, 2026, subject to shareholders' approval. The proposal is in accordance with applicable provisions and is subject to approval of the company's shareholders. The company will announce record date details related to bonus issue soon, with investors required to own the stock before the record date to become eligible for the payout. On September 23, the board approved the issuance of bonus shares in the ratio of 1:1, with every eligible shareholder receiving bonus equity share of Re 1 each for every one fully paid-up equity share of Re 1 each. The company plans to issue 10.46 crore bonus shares, aggregating to ₹10.46 crore, with the bonus shares to be credited or dispatched within two months of board approval, subject to statutory and shareholder clearances, with the process expected to be completed by November 22, 2026.
As reported by CNBC TV18 and ET Now, shares of Concord Biotech have demonstrated exceptional performance with 7.22% gains over the past week and 6.44% in two weeks, while the stock has gained 18.22% in three months and 50.82% over the past six months. The stock has advanced 16.61% on a year-to-date basis, demonstrating strong investor confidence ahead of the bonus issue consideration. While the shares hit a 52-week high of ₹1,702.10 per share on September 19, 2025, they touched a year's low of ₹987.05 per share on April 2, 2026. The stock has a return on equity (ROE) of 17.72% and has surged around 43.9% in six months, 19.4% in three months, and 17.58% in 2026 so far. According to latest reports, the stock closed 1.87% higher at ₹1,559.20 per share on BSE with a market capitalisation of ₹16,311.76 crore on Wednesday, September 23. With today's gains, the stock turned positive for the month.
As reported by CNBC TV18, at the end of the June quarter, promoter entities held 44.08% stake in the company, while public shareholders held 55.92% stake. Among the public shareholders, multiple Jhunjhunwala family trusts hold a total of 24.09% stake in the company. The Aryavir Jhunjhunwala Discretionary Trust, Aryaman Jhunjhunwala Discretionary Trust and Nishtha Jhunjhunwala Discretionary Trust hold 8.03% stake each in the company, respectively. Close to 79,000 small retail shareholders, or those with authorized share capital of up to ₹2 lakh, had a 7.03% stake in the company at the end of the June quarter. According to latest BSE data as of September 23, the Jhunjhunwala family trusts maintain their 8% shareholding each in the company.
In addition to the bonus issue approval, Concord Biotech's board of directors also approved increase in authorised share capital of the company. The board increased the authorised share capital from ₹11 crore, divided into 11 crore equity shares of Re 1 each, to ₹22 crore divided into 22 crore shares of Re 1 each. The board approved the creation of an additional 11 crore shares of Re 1, effectively doubling the company's authorised share capital. The bonus shares will be issued by capitalising the company's share premium account, with Concord Biotech utilising ₹10.46 crore from its share premium reserves for the issue, compared with a balance of ₹81.97 crore as of March 31, 2026. This enhancement provides the company with greater flexibility for future fundraising and corporate actions. Following the bonus issue, the company's paid-up equity share capital will double from ₹10.46 crore to ₹20.92 crore, with the total number of outstanding equity shares rising to 20.92 crore.
According to CNBC TV18, Concord Biotech reported strong recent financial results showing significant growth. The company reported a net profit of ₹58.5 crore in Q1FY27, representing a 32.8% increase from ₹44.05 crore in the same quarter last year. Its net revenue increased 26.2% to ₹257.4 crore from ₹202.4 crore in the year-ago period. The company's earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 34.2% to ₹82.4 crore from ₹61.3 crore, while its margin expanded to 32% from 30.1% in the year-ago period. The company's earnings were reported on July 31. Following the bonus issue, the company's paid-up equity share capital will double from ₹10.46 crore to ₹20.92 crore, with the total number of outstanding equity shares rising to 20.92 crore.
According to latest NSE data as of September 23, 2026, Concord Biotech shares ended at ₹1,560.30 per share, gaining 1.82% on the National Stock Exchange. The stock has demonstrated strong momentum with 17% gains from the beginning of the year, 2% advance over a month, and 52% climb over six months. The stock had hit a 52-week high of ₹1,695 on September 22, 2025, and touched a 52-week low of ₹987 on April 2, 2026. With a total market capitalisation of ₹16,323.27 crore as of September 23, 2026, the stock continues to attract investor attention following the board's approval of the bonus issue and capital enhancement proposals. The stock has shown absolute changes of ₹105.05 in one week, ₹94.40 in two weeks, ₹240.25 in three months, ₹525.40 in six months and ₹222.15 on a year-to-date basis.
